2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.19 Weber

PP01.19 Weber - Poster

Pdf Summary

The study analyzed 55 patients with advanced non-small cell lung cancer (NSCLC) carrying EGFR mutations and treated with osimertinib. Among them, nearly half developed resistance mechanism upon disease progression, split equally between on- and off-target mechanisms. Interestingly, there was no significant difference in progression-free survival (PFS) or overall survival (OS) between patients with on-target versus off-target resistance on subsequent therapy. The research sheds light on the impact of resistance mechanisms to osimertinib on post-progression outcomes for NSCLC patients. Figures and tables detailed patient characteristics, testing methods, and treatment regimens. For instance, a case study illustrated a patient with EGFR-expressing NSCLC who developed MET amplification resistance to osimertinib, leading to combined treatment with capmatinib resulting in a treatment response. The findings suggest the importance of understanding resistance mechanisms to guide treatment decisions in patients with EGFR-mutated NSCLC receiving osimertinib. The study was conducted at the University of Colorado School of Medicine and provides valuable insights for clinicians managing patients with advanced NSCLC.

Keywords

NSCLC

EGFR mutations

osimertinib

resistance mechanisms

progression-free survival

overall survival

on-target mechanisms

off-target mechanisms

MET amplification resistance

treatment response